Key result
Candesartan reduced brachial and central systolic BP the most regardless of baseline haemodynamic profile, while AIx and PPA predicted bisoprolol response.
Why the study?
Essential hypertension is characterised by haemodynamic alterations, and whether baseline haemodynamic indices predict the blood pressure lowering effects of different antihypertensive drug classes was tested.
RCT (n=53)
Double-blind
Randomized crossover
Yes
Answers are grounded in this paper and cite their sources.
Background: Essential hypertension is characterised by alterations in haemodynamics.Hence haemodynamic profiling could lead to improved blood pressure (BP) control in these patients.We tested if baseline haemodynamic indices predict the BP lowering effects of different classes of antihypertensive drugs in hypertensive patients.Methods: In this double-blind placebo-controlled crossover study we randomised 53 hypertensive patients to receive doxazosin 4 mg, candesartan 16 mg, bisoprolol 5 mg, isosorbide mononitrate (ISMN) 50 mg, and placebo daily for 6 weeks.Brachial and central BP, augmentation index (AIx), aortic pulse wave velocity (aPWV), stroke volume (SV), cardiac output (CO), peripheral vascular resistance (PVR), and pulse pressure amplification (PPA) were measured at baseline and after each drug.Results: Baseline AIx and PPA determined BP reduction with antihypertensive therapy, particularly with bisoprolol.In patients with low baseline AIx (1.7e28.9%)and high PPA (1.22e1.87),bisoprolol had a weak antihypertensive effect, while the opposite was observed in patients with high AIx (36.3e48.2%)and low PPA (1.05e1.11).With candesartan, BP reduction was the largest, regardless of baseline AIx or PPA levels.Conclusions: Our study suggests that ARBs reduce BP the most irrespective of the underlying haemodynamic profile.Antihypertensive therapy guided by AIx and PPA may have some merit
No takes yet. Share an insight, caveat, or question.
Serg et al. (2014) conducted an RCT in Essential hypertension (n=53). Candesartan, doxazosin, bisoprolol, and isosorbide mononitrate vs. Placebo was evaluated on Brachial systolic blood pressure (mmHg) (p=<0.001). Candesartan reduced brachial and central systolic BP the most regardless of baseline haemodynamic profile, while AIx and PPA predicted bisoprolol response.
Synapse has enriched 10 related papers. Consider them for comparative context: